Progress of leukoaraiosis volume is inhibited to one-forth by correcting the platelet hyper-aggregability. A comparison study between correcting and non-correcting group

Shigekiyo Fujita

Institute for advanced Neurological Medicine and Computed Imaging, Ishikawa Hospital

    The author found significant high incidence, 90.4%, of leukoaraiosis in the platelet hyper-aggregability patients (Acta Nourol Scand 105: 445-9, 2002).   In comparison study of matched two groups, very little aggravation of leukoaraiosis was observed in correcting group of the platelet hyper-aggregability than non-correcting group (Internat Pshychogeriat 17: 689-98, 2005).  As a further confirmation, comparison study of aggravation volume in two groups is performed.
    On examples with platelet hyper-aggregability and without hypertension, at random-entry two groups: correcting (group A: n=11) and non-correcting (group B: n=12), with 1.5 years observation period, comparison of the amount of aggravation volume of leukoaraiosis measured using NIH Image is performed.  Platelet aggregability was estimated by an optical analytical method using two different concentrations each of ADP and collagen (the double ADP method).  By this apparatus, platelet hyper-aggregability and normal-aggregability were easily and exactly defined.
    Initial volume of leukoaraiosis was 30.8cm³ on group A and 29.6cm³ on group B, and 1 year after it was 32.1cm³ and 34.2cm³, respectively.  Yearly increase of leukoaraiosis volume was 4.1% on group A and 16.1% on group B (p=0.00011).
    In conclusion, aggravation of leukoaraiosis volume was inhibited to one-forth by correcting the platelet hyper-aggregability, and then severe leukoaraiosis could be prevented.

Address correspondence to Dr. Shigekiyo Fujita, Institute for advanced Neurological Medicine and Computed Imaging, Ishikawa Hospital (150, 2-Chome, Bessho, Besso-cho, Himeji 671-0221, Japan)